ClinicalTrials.gg
CompletedNCT06804096Updated Aug 4, 2026

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

A Phase 4 interventional study of Faropenem and Co-amoxiclav in Pneumonia, Community-Acquired and Bacterial Pneumonia, sponsored by Dr. Md. Alimur Reza. Completed at 2 sites in Bangladesh. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Dr. Md. Alimur Reza · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.

02

Conditions studied

  • Pneumonia, Community-Acquired
  • Bacterial Pneumonia

Keywords

  • CABP
  • Faropenem
03

In context

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

This study's enrollment of 129 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Dr. Md. Alimur Reza is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged between 18 to 65 years.
  • Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):

    1. Fever (body temperature > 38.0 °C (100.4 °F) measured orally)
    2. Shortness of breath
    3. New onset or increased cough with or without sputum production.
    4. Chest pain.
  • Have radiographically documented bacterial pneumonia:

    1. Infiltrates in a unilateral, lobar distribution
    2. Diffuse opacities or white condensed area
    3. The alveoli fill with white inflammatory fluid

Exclusion criteria

Exclusion Criteria:

  • Patients with severe pneumonia (Clinical \& Radiological Assessment)
  • Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)
  • Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.
  • History of , known or suspected , or intolerance to any of the study drugs.
  • Intake of an antibiotic within the last 48 hours before study admission.
  • History of hospitalization within the last 28 days.
  • Patients in pregnancy and lactational state.
  • Patients with Renal impairment (screening \< 30mL/min).
  • Significant hepatic impairment ( > three times the ).
  • Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.
  • Patients who are taking medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).
  • Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.
  • Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Arm 1

    Arm 1: Tab. Faropenem 200mg three times daily with standard care.

    Drug: Faropenem

  • Active comparator
    Arm 2

    Arm 2: Tab. Co-Amoxiclav 625mg three times daily and Tab. Clarithromycin 500mg two times daily with standard care.

    Drug: Co-amoxiclav · Drug: Clarithromycin 500 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Cure Rate between two groups.

    The clinical cure rate will be defined as significant improvement of clinical signs and symptoms at the end of treatment or follow-up, without new onset of symptoms, any complications, or the need for further antimicrobial therapy.

    Time frame: 10-14 days

  2. Percentage of patients withdrawn from the study due to adverse events between two groups.

    To compare the percentage of patients withdrawn from the study due to adverse events between two groups.

    Time frame: 10-14 Days

Secondary outcomes

  1. Early Clinical Response (ECR) between two groups.

    ECR will be defined as at least one improvement in the symptom mentioned below within 3 ± 1 days after the first dose of the study drug. 1. Fever 2. Decreased shortness of breath. 3. Decreased chest pain. 4. Decreased cough. 5. Decreased sputum/mucous production. 6. Sense of wellbeing.\]

    Time frame: 3 - 4 days

  2. All-cause mortality between two groups

    To compare the all-cause mortality rate between two groups

    Time frame: 10-14 days

  3. Number of patients who needed hospitalization in both groups

    Time frame: 28 days

  4. Number of patients who needed Intensive Care Unit (ICU) support in both groups.

    Time frame: 28 Days

  5. Frequency of Adverse Events & Serious Adverse Events between two groups.

    Time frame: 28 Days

07

Study locations

2 sites
  • Popular Medical College & Hospital
    Dhaka, Dhaka Division 1205, Bangladesh
  • Shaheed Suhrawardy Medical College & Hospital
    Dhaka, Dhaka Division 1205, Bangladesh
08

References and documents

Publications

  • Lode H, Magyar P, Muir JF, Loos U, Kleutgens K; International Gatifloxacin Study Group. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clin Microbiol Infect. 2004 Jun;10(6):512-20. doi: 10.1111/j.1469-0691.2004.00875.x. PubMed 15191378 ↗
  • Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98. doi: 10.1586/14787210.5.2.185. PubMed 17402834 ↗
  • Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008 May;86(5):408-16. doi: 10.2471/blt.07.048769. PubMed 18545744 ↗
  • Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008 Oct 1;198(7):962-70. doi: 10.1086/591708. PubMed 18710327 ↗
  • Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011 May;52 Suppl 4:S296-304. doi: 10.1093/cid/cir045. PubMed 21460288 ↗
  • Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013 Nov;68(11):1057-65. doi: 10.1136/thoraxjnl-2013-204282. PubMed 24130229 ↗
  • Peto L, Nadjm B, Horby P, Ngan TT, van Doorn R, Van Kinh N, Wertheim HF. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014 Jun;108(6):326-37. doi: 10.1093/trstmh/tru058. Epub 2014 Apr 29. PubMed 24781376 ↗
  • File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010 Mar;122(2):130-41. doi: 10.3810/pgm.2010.03.2130. PubMed 20203464 ↗
  • Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L; CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015 Jul 30;373(5):415-27. doi: 10.1056/NEJMoa1500245. Epub 2015 Jul 14. PubMed 26172429 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jan 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Jan 31, 2025
StartActual
Feb 20, 2025
Primary completionActual
Jan 12, 2026
CompletionActual
Jan 26, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804096
Lead sponsor
Dr. Md. Alimur Reza
Responsible party
Dr. Md. Alimur Reza (Director, Beximco Pharmaceuticals Ltd.) — Sponsor-investigator
First posted
Jan 31, 2025
Start date
Feb 20, 2025
Primary completion
Jan 12, 2026
Completion
Jan 26, 2026
Last update
Aug 4, 2026

Study contacts

Prof. Khan Abul Kalam Azad
principal investigator · Popular Medical College Hospital
Prof. Quazi Tarikul Islam, MBBS, FCPS, FACP (USA), FRCP,
study director · Popular Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fropenem

Start the discussion